Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
Investing.com - Morgan Stanley (NYSE:MS) has initiated coverage on Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NS:SUNP) with an Overweight rating and a price target of INR1,960.00.
The investment bank cited Sun Pharma’s successful transition from generic to specialty drugs as a key factor driving the company’s earnings upgrade cycle and outperformance against peers over the past five years. Morgan Stanley also highlighted the company’s sector-leading EBITDA margin, return ratio, and strong balance sheet as factors supporting multiple re-rating.
Sun Pharma maintains a leadership position in the domestic formulations branded generic market with approximately 8.3% market share by revenue for fiscal year 2025, supported by its strong chronic portfolio. The company is also gaining traction in the U.S. specialty segment, particularly in dermatology, oncology, and ophthalmology through products including Ilumya, Winlevi, Cequa, Leqselvi, and recently acquired Unloxcyt.
The pharmaceutical company’s specialty pipeline includes GLP-1 agnostic (Utreglutide), psoriatic arthritis treatment, and pain in osteoarthritis candidate MM-II, positioning it well in high-value global markets. Sun Pharma acquired Unloxcyt (cosibelimab) in March 2025 from Checkpoint for US$355 million.
Morgan Stanley projects Sun Pharma to deliver an 11% earnings CAGR from fiscal year 2025 to 2027, supported by stable revenue and margin profiles on a normalized basis, with the company expected to maintain an average RoCE of approximately 20% during this period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.